Integrin v 3 targeted therapy for Kaposi s sarcoma with an in vitro evolved antibody 1
|
|
- Dustin Lambert
- 6 years ago
- Views:
Transcription
1 Integrin v 3 targeted therapy for Kaposi s sarcoma with an in vitro evolved antibody 1 CHRISTOPH RADER, 2 MIKHAIL POPKOV, JOHN A. NEVES, AND CARLOS F. BARBAS III 2 Department of Molecular Biology and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California, USA SPECIFIC AIMS The goal of this study was to evaluate integrin v 3 as a molecular target for antibody therapy for Kaposi s sarcoma (KS). We used in vitro evolution based on phage display to generate a humanized and affinitymatured antibody directed to integrin v 3 to evaluate tumor targeting and tumor growth inhibition in a mouse model of KS. PRINCIPAL FINDINGS 1. In vitro evolution of antibody JC-7U directed to integrin v 3 Using a phage display strategy that preserves only the original CDR3 sequences of light and heavy chain while subjecting the remaining sequence to selection from naive human V gene libraries, we previously reported the full humanization of mouse monoclonal antibody (mab) LM609 directed to human integrin v 3. Here we further improved the affinity of humanized LM609 using a phage display strategy for sequential and parallel optimization of three complementarity determining regions (LCDR1, HCDR1, and HCDR3) of the antibody molecule. The evolved Fab, designated JC-7U, had an affinity of 150 pm and was converted into IgG1 using a new mammalian expression vector (Fig. 1). 2. Tumor targeting of antibody JC-7U in a mouse model of Kaposi s sarcoma A previously described nude mouse model of KS based on human KS cell line SLK was used for our studies. As an isotype control for JC-7U IgG1, we used human b12 IgG1, which binds to gp120 of HIV-1. Flow cytometry revealed strong binding of JC-7U IgG1 to SLK cells, whereas no binding was detected for b12 IgG1. For in vivo studies, tumor induction was performed by subcutaneous injection of SLK cells in the right flank of nude mice. We first analyzed tumor targeting by injecting 100 g of JC-7U IgG1 or b12 IgG1 into the tail vein of mice with an established SLK xenograft. After 24 h, tumor, lung, liver, and spleen were removed and processed for the detection of bound human IgG1 by immunohistochemistry. As shown in Fig. 2, JC-7U IgG1 was found to have intensely penetrated the tumor tissue whereas control antibody b12 IgG1 revealed only slight nonspecific uptake. By contrast, neither JC-7U IgG1 nor b12 IgG1 were found in normal tissue. 3. Antibody JC-7U inhibits tumor growth in a mouse model of Kaposi s sarcoma With the selective tumor targeting of JC-7U IgG1 established, we next analyzed whether JC-7U IgG1 can inhibit tumor growth. Three different groups of five animals each were treated on days 1, 4, 7, 10, and 13 after tumor induction. Each treatment involved a 200 l tail vein injection of 1) 0.5 mg/ml JC-7U IgG1 in PBS, 2) 0.5 mg/ml b12 IgG1 in PBS, or 3) PBS alone. Thus, animals in the antibody groups received five doses of 100 g or 5 mg/kg. For comparison, clinical studies with Vitaxin, another humanized derivative of LM609, have used doses up to 4 mg/kg with little or no toxicity, which suggests that our dosing regimen is in a clinically relevant range. Study of animals treated with JC-7U IgG1 revealed no obvious signs of toxicity for this protein, as indicated by no weight loss or behavioral change during the course of therapy. Tumor volumes of treated animals were measured every third day starting on day 9 and ending on day 54 (Fig. 3). Tumor growth in animals treated with PBS or b12 IgG1 revealed no difference compared with tumor growth in untreated animals, resulting in an average tumor volume of 650 and 685 mm 3, respectively, tumor growth in animals treated with JC-7U IgG1 was notably slower (Fig. 3). The difference in tumor growth was statistically significant (P0.05) from day 27 until the end of the experiment 27 days later. On day 54, average tumor volume in the animals treated with JC-7U IgG1 was 292 mm 3, which is 45% of the average tumor volume observed in the control groups. As an additional measurement, all tumors were surgically removed on day 54 and weighed. The average tumor weight in the three treatment groups confirmed the results obtained for 1 To read the full text of this article, go to fasebj.org/cgi/doi/ /fj fje; to cite this article, use FASEB J. (October 18, 2002) /fj fje 2 Correspondence: Department of Molecular Biology, BCC-526, The Scripps Research Institute, North Torrey Pines Road, La Jolla, CA 92037, USA. crader@scripps.edu and carlos@scripps.edu /02/ FASEB
2 Figure 1. Tumor growth inhibition in a nude mouse model of KS in the presence of JC-7U IgG1. JC-7U IgG1 (black) or control antibody b12 IgG (white circles) was given in five doses of 5 mg/kg every third day starting on day 1 after tumor induction. Statistically significant differences in tumor volume were observed 14 days after the last treatment until the end of the experiment. Shown are average tumor volumes sd (n5 for both groups). the measurement of the tumor volume. We did not observe growth inhibition in vitro at or beyond the administered in vivo concentration of JC-7U IgG1, Figure 3. Tumor targeting of JC-7U IgG1. JC-7U IgG1 (A, E) and control antibody b12 IgG1 (B, F) were injected into the tail vein of nude mice with an established human KS tumor. After 24 h, tumor (A, B) and lung tissue (E, F) were removed and processed for the detection of bound human IgG using goat anti-human IgG secondary antibodies. C, D) Mouse endothelial cells that infiltrate the human KS tumor were detected with a rat anti-mouse CD31 mab, followed by rabbit anti-rat IgG secondary antibodies. Note that the sites of CD31 expression and JC-7U IgG1 tumor penetration overlap. Scale bar 50 m for panels A F. suggesting that antibody-dependent cellular cytotoxicity (ADCC) is the main mechanism of tumor growth inhibition of human JC-7U IgG1 in our nude mouse model of KS. Like its parental antibody, mouse mab LM609, JC-7U binds to human but not mouse integrin v 3. In the SLK xenograft, JC-7U recognizes human integrin v 3 expressed by tumor cells but not mouse integrin v 3 expressed by angiogenic endothelial cells. Thus, the reduction of KS tumor growth in the presence of JC-7U is not an antiangiogenic effect but can be attributed to a specific, direct response against the tumor, which allows us to dissect out the antitumor effect of this antibody therapy. 4. Antibody JC-7U partially blocks the binding of HIV-1 Tat protein to integrin v 3 Figure 2. Schematic diagram illustrating the in vitro evolution of antibody JC-7U. Because of its high affinity and its high degree of humanization, JC-7U IgG1 is an excellent drug candidate for therapeutic applications that involve integrin v 3 as the molecular target. Of particular interest is therapy for KS, breast cancer, melanoma, and other cancers in which integrin v 3 is expressed on both angiogenic endothelial cells and tumor cells, a dual antiangiogenic and antitumor strike with a single drug. Mouse sequences are shown in yellow, human sequences in blue, optimized sequences in red. Based on published evidence that the HIV-1 Tat protein can act as a growth factor for KS by binding to RGD receptors, including integrin v 3, that are expressed on the surface of KS cells, we investigated whether JC-7U can interfere with this interaction. We established a binding assay in which a mixture of human integrin v 3 and synthetic HIV-1 Tat-biotin was incubated in solution in the presence or absence of JC-7U Fab. Complexes of integrin v 3 and Tat-biotin were then captured with immobilized streptavidin and were detected by using the anti- 3 mouse mab AP-3, which does not interfere with JC-7U binding, followed by goat anti-mouse secondary antibodies. Background signals were determined by running the same assay in the absence of Tat-biotin. In the absence of JC-7U, a strong signal above background was observed, which revealed INTEGRIN V 3 TARGETED THERAPY OF KAPOSI S SARCOMA 2001
3 an interaction of integrin v 3 and Tat-biotin. In the presence of a threefold molar excess of JC-7U Fab over Tat-biotin or at equimolar concentrations, the signal was reduced to 45%. The same reduction was observed in the presence of JC-7U IgG1. Thus, JC-7U partially blocks the binding of HIV-1 Tat protein to human integrin v 3. CONCLUSIONS AND SIGNIFICANCE In view of the fact that KS tumors are of endothelial origin and characterized by intense angiogenesis, it is logical that many of the recently developed antiangiogenic drugs are being studied for the treatment of KS. With the emerging picture of KS pathogenesis and angiogenesis, molecular targets are being revealed that may provide effective targeting of drugs to both the KS vasculature and the KS tumor itself. We hypothesized that integrin v 3 might fulfill these criteria. Integrin v 3 is up-regulated on endothelial cells in response to angiogenic growth factors and has been established as a target for antiangiogenic therapy. Soluble antagonists of integrin v 3 such as mab LM609, RGD peptides, or peptidomimetics, initiate endothelial cell apoptosis and thereby inhibit angiogenesis. In addition to its expression on the surface of angiogenic endothelial cells, integrin v 3 is expressed on the surface of tumor cells in a variety of cancers. In melanoma and breast cancer, for example, tumor progression and metastasis correlate with integrin v 3 expression. Thus, independent of its role in tumor angiogenesis, integrin v 3 is likely to be functionally implicated in the pathogenesis of a variety of cancers. This is particularly apparent for KS, where a central position of integrin v 3 within angiogenesis and KS pathogenesis has emerged, suggesting that integrin v 3 may become a prime molecular target for KS therapy. The hypervascular morphology of KS makes it highly accessible to therapeutic macromolecules, such as antibodies, whose general applicability for cancer therapy is limited by poor tumor penetration. With JC-7U, we developed a highly advanced drug candidate for therapeutic applications that involve integrin v 3 as the molecular target. JC-7U IgG1 was found to selectively target tumors in a mouse model of KS and inhibit tumor growth at a therapeutically relevant dose. We anticipate that the tumor growth-inhibiting activity of JC-7U will be even more effective in KS patients as compared with mouse models of KS. First, in the presence of human angiogenic endothelial cells, JC-7U is expected to exert an antiangiogenic effect based on initiation of endothelial cell apoptosis and ADCC in addition to an antitumor effect. Second, in AIDS-associated KS, JC-7U will partially block the binding of HIV-1 Tat protein to human integrin v 3 and, thus, potentially diminish its tumor growth-promoting activity Vol. 16 December 2002 The FASEB Journal RADER ET AL.
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21 Table 1 Binding parameters of Fab directed to human integrin αvβ3 a Fab k on /10 4 k off /10 4 K d (M 1 s 1 ) (s 1 ) (nm) Mouse LM609 b Humanized LM (18 b ) 5.9 (5.4 b ) 2.6 (3.0 b ) JC-7U a Binding kinetics were determined by using surface plasmon resonance. Human integrin αvβ3 was immobilized on the sensor chip. K d was calculated from k off /k on. All Fab fragments were produced by using E. coli expression. b Data from Rader et al. (10).
22 Fig. 1 Figure 1. Affinity maturation of humanized LM609 by CDR walking. CDR walking involves the sequential or parallel optimization of CDRs by focused mutagenesis and subsequent selection by phage display. Shown is a combination of sequential and parallel CDR optimization used for the affinity maturation of humanized LM609. Randomized sequences are hatched; optimized sequences are black. CDR3 of the light chain was optimized first, followed by a parallel optimization of CDR1 and CDR3 of the heavy chain. Optimized CDR1 and CDR3 of the heavy chain were combined in the last step. This focused mutagenesis strategy involved the randomization of four hypervariable codons in each targeted CDR encoding sequence. LC, light chain; HC, heavy chain.
23 Fig. 2 Figure 2. Randomized and selected sequences of LCDR3, HCDR1, and HCDR3 for one of the selected clones, designated JC-7U. The top and middle panels show the four codons of each CDR that were subjected to randomization by NNK (nnk in the figure) doping (n = a, c, g, or t; k = g or t). The bottom panel shows the selected NNK codons and their corresponding amino acids (single-letter amino acid code). As shown in bold type, 10 of 12 codons but only 5 of 12 amino acids differed between the original and the selected sequence. No amino acid mutations in nonrandomized CDR and framework regions were found.
24 Fig. 3 Figure 3. Overlayed Biacore 1000 sensorgrams obtained from the binding of humanized LM609-7 Fab and JC-7U Fab to immobilized human integrin αvβ3. For association, Fab fragments were injected at 80 nm between t = 125 s and t = 370 s, with a flow rate of 10 µl/min. For dissociation, the flow rate was increased to 50 µl/min. RU, resonance units.
25 Fig. 4 Figure 4. Flow cytometry histograms demonstrating the binding of JC-7U Fab and humanized LM609-7 Fab to the human KS cell line SLK. For indirect immunofluorescence staining, cells were incubated with 2 µg/ml JC-7U Fab (bold line) or 2 µg/ml humanized LM609-7 (fine line) or buffer alone (dotted line), followed by FITC-conjugated secondary antibodies. The y axis gives the number of events in linear scale, the x axis the fluorescence intensity in logarithmic scale. Note that JC-7U Fab revealed a slightly stronger binding than did humanized LM This difference was confirmed at Fab concentrations of 200 and 20 ng/ml and was also seen when human melanoma M21 cells were used instead of SLK cells.
26 Fig. 5 Figure 5. Vector PIGG designed for antibody expression in mammalian cells. The 9-kb vector contained both heavy- and light-chain expression cassettes driven by a bidirectional CMV promoter construct. Cloning sites for the variable domain encoding sequences were designed for compatibility with pcomb3 phage display vectors. By using PIGG, Fab selected by phage display can be readily converted into IgG.
27 Fig. 6 Figure 6. JC-7U IgG1 did not inhibit the growth of human KS cell line SLK in vitro. Shown is a proliferation assay based on [ 3 H]thymidine incorporation during DNA synthesis. None of the tested concentrations in a range of 0.1 nm to 1 µm revealed a significant difference between JC-7U IgG1 and the control antibody b12 IgG1. Background signals were determined by running the same assay in the absence of antibody and were defined as 0% inhibition (n = 3).
28 Fig. 7 Figure 7. Tumor targeting of JC-7U IgG1. JC-7U IgG1 (A and E) and control antibody b12 IgG1 (B and F) were injected into the tail vein of nude mice with an established human KS tumor. After 24 h, tumor (A and B) and lung tissue (E and F) were removed and processed for the detection of bound human IgG by using goat anti-human IgG secondary antibodies. C, D) Mouse endothelial cells that infiltrate the human KS tumor were detected with a rat anti-mouse CD31 mab followed by rabbit anti-rat IgG secondary antibodies. Note that the sites of CD31 expression and JC-7U IgG1 tumor penetration overlap. Scale bar = 50 µm for A-F.
29 Fig. 8 Figure 8. Tumor growth inhibition in a nude mouse model of KS in the presence of JC-7U IgG1. JC-7U IgG1 (black circles) or control antibody b12 IgG1 (white circles) was given in five doses of 5 mg/kg every third day starting on day 1 after tumor induction. Statistically significant differences in tumor volume were observed 14 days after the last treatment until the end of the experiment. Shown are average tumor volumes ± SD (n = 5 for both groups).
30 Fig. 9 Figure 9. Tumor growth inhibition in a nude mouse model of KS in the presence of JC-7U IgG1. Shown are tumor weights after treatment with JC-7U IgG1, b12 IgG1, or PBS. Tumors were removed surgically on day 54 after tumor initiation and weighed. Tumor weights are averages ± SD (n = 5 for JC-7U and b12; n = 4 for PBS [1 animal in this PBS group died before day 54]). The differences between treatment with JC-7U IgG1 and b12 IgG1 (P=0.0019) or PBS (P=0.0004) were statistically significant.
31 Fig. 10 Figure 10. JC-7U Fab partially blocked the binding of HIV-1 Tat protein to human integrin αvβ3. A mixture of human integrin αvβ3 and synthetic HIV-1 Tat-biotin was incubated in solution in the presence or absence of JC-7U Fab. Complexes of integrin αvβ3 and Tat-biotin were then captured with immobilized streptavidin and were detected by using an independent mouse mab directed to integrin subunit β3 followed by goat anti-mouse secondary antibodies. Background signals were determined by running the same assay in the absence of Tat-biotin. Background-depleted signals are shown (n = 3; P=0.0058).
Supplementary Figure 1. Properties of various IZUMO1 monoclonal antibodies and behavior of SPACA6. (a) (b) (c) (d) (e) (f) (g) .
Supplementary Figure 1. Properties of various IZUMO1 monoclonal antibodies and behavior of SPACA6. (a) The inhibitory effects of new antibodies (Mab17 and Mab18). They were investigated in in vitro fertilization
More informationSupplemental Figure 1
Supplemental Figure 1 1a 1c PD-1 MFI fold change 6 5 4 3 2 1 IL-1α IL-2 IL-4 IL-6 IL-1 IL-12 IL-13 IL-15 IL-17 IL-18 IL-21 IL-23 IFN-α Mut Human PD-1 promoter SBE-D 5 -GTCTG- -1.2kb SBE-P -CAGAC- -1.kb
More informationCrystallization-grade After D After V3 cocktail. Time (s) Time (s) Time (s) Time (s) Time (s) Time (s)
Ligand Type Name 6 Crystallization-grade After 447-52D After V3 cocktail Receptor CD4 Resonance Units 5 1 5 1 5 1 Broadly neutralizing antibodies 2G12 VRC26.9 Resonance Units Resonance Units 3 1 15 1 5
More informationSupplementary Data 1. Alanine substitutions and position variants of APNCYGNIPL. Applied in
Supplementary Data 1. Alanine substitutions and position variants of APNCYGNIPL. Applied in Supplementary Fig. 2 Substitution Sequence Position variant Sequence original APNCYGNIPL original APNCYGNIPL
More informationSUPPLEMENTARY INFORMATION
doi:10.1038/nature11095 Supplementary Table 1. Summary of the binding between Angptls and various Igdomain containing receptors as determined by flow cytometry analysis. The results were summarized from
More informationhexahistidine tagged GRP78 devoid of the KDEL motif (GRP78-His) on SDS-PAGE. This
SUPPLEMENTAL FIGURE LEGEND Fig. S1. Generation and characterization of. (A) Coomassie staining of soluble hexahistidine tagged GRP78 devoid of the KDEL motif (GRP78-His) on SDS-PAGE. This protein was expressed
More informationEssential Medium, containing 10% fetal bovine serum, 100 U/ml penicillin and 100 µg/ml streptomycin. Huvec were cultured in
Supplemental data Methods Cell culture media formulations A-431 and U-87 MG cells were maintained in Dulbecco s Modified Eagle s Medium. FaDu cells were cultured in Eagle's Minimum Essential Medium, containing
More information2012 Landes Bioscience. Do not distribute.
Report mabs 4:5, 600-613; September/October 2012; 2012 Landes Bioscience Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis Palanisamy
More informationAntigen Receptor Structures October 14, Ram Savan
Antigen Receptor Structures October 14, 2016 Ram Savan savanram@uw.edu 441 Lecture #8 Slide 1 of 28 Three lectures on antigen receptors Part 1 (Today): Structural features of the BCR and TCR Janeway Chapter
More informationA549 and A549-fLuc cells were maintained in high glucose Dulbecco modified
Cell culture and animal model A549 and A549-fLuc cells were maintained in high glucose Dulbecco modified Eagle medium supplemented with 10% fetal bovine serum at 37 C in humidified atmosphere containing
More informationSupplementary Figure 1.TRIM33 binds β-catenin in the nucleus. a & b, Co-IP of endogenous TRIM33 with β-catenin in HT-29 cells (a) and HEK 293T cells
Supplementary Figure 1.TRIM33 binds β-catenin in the nucleus. a & b, Co-IP of endogenous TRIM33 with β-catenin in HT-29 cells (a) and HEK 293T cells (b). TRIM33 was immunoprecipitated, and the amount of
More informationBiology Open (2014) 000, 1 10 doi: /bio
(2014) 000, 1 10 doi:10.1242/bio.201410041 Supplementary Material Michael Brauchle et al. doi: 10.1242/bio.201410041 Fig. S1. Alignment of GFP, sfgfp, egfp, eyfp, mcherry and mruby2. Sequence-based alignment
More informationImmune surveillance: The immune system can recognize and destroy nascent malignant cells
Immune surveillance: The immune system can recognize and destroy nascent malignant cells Control Escape APC T C T H B NKT NK Innate Tumor T cells are believed to play a major role in controlling tumor
More informationSupplementary Figure 1. Generation of knockin mice expressing L-selectinN138G. (a) Schematics of the Sellg allele (top), the targeting vector, the
Supplementary Figure 1. Generation of knockin mice expressing L-selectinN138G. (a) Schematics of the Sellg allele (top), the targeting vector, the targeted allele in ES cells, and the mutant allele in
More informationSuperior Fluorescent Labeling Dyes Spanning the Full Visible Spectrum...1. Trademarks: HiLyte Fluor (AnaSpec, Inc.)
Table of Contents Fluor TM Labeling Dyes Superior Fluorescent Labeling Dyes Spanning the Full Visible Spectrum....1 Fluor TM 405 Dye, an Excellent Alternative to Alexa Fluor 405 & DyLight 405....2 Fluor
More informationSupplemental Figure 1. Cell-bound Cetuximab reduces EGFR staining intensity. Blood
Antibody-mediated depletion of CD19-CAR T cells Supplemental 1 Supplemental Materials Supplemental Figure 1. Supplemental Figure 1. Cell-bound Cetuximab reduces EGFR staining intensity. Blood cells were
More informationSuppl Video: Tumor cells (green) and monocytes (white) are seeded on a confluent endothelial
Supplementary Information Häuselmann et al. Monocyte induction of E-selectin-mediated endothelial activation releases VE-cadherin junctions to promote tumor cell extravasation in the metastasis cascade
More informationFigure S1. Western blot analysis of clathrin RNA interference in human DCs Human immature DCs were transfected with 100 nm Clathrin SMARTpool or
Figure S1. Western blot analysis of clathrin RNA interference in human DCs Human immature DCs were transfected with 100 nm Clathrin SMARTpool or control nontargeting sirnas. At 90 hr after transfection,
More informationwere isolated from the freshly drawn blood of healthy donors and ACS patients using the
Supplemental Figure 1. Quality control of CD4 + T-cell purification. CD4 + T cells were isolated from the freshly drawn blood of healthy donors and ACS patients using the RosetteSep CD4 + T Cell Enrichment
More informationPearson r = P (one-tailed) = n = 9
8F4-Specific Lysis, % 1 UPN1 UPN3 8 UPN7 6 Pearson r =.69 UPN2 UPN5 P (one-tailed) =.192 4 UPN8 n = 9 2 UPN9 UPN4 UPN6 5 1 15 2 25 8 8F4, % Max MFI Supplementary Figure S1. AML samples UPN1-UPN9 show variable
More informationSUPPLEMENTARY INFORMATION
doi:10.1038/nature10134 Supplementary Figure 1. Anti-inflammatory activity of sfc. a, Autoantibody immune complexes crosslink activating Fc receptors, promoting activation of macrophages, and WWW.NATURE.COM/NATURE
More information(a) Schematic diagram of the FS mutation of UVRAG in exon 8 containing the highly instable
Supplementary Figure 1. Frameshift (FS) mutation in UVRAG. (a) Schematic diagram of the FS mutation of UVRAG in exon 8 containing the highly instable A 10 DNA repeat, generating a premature stop codon
More informationAnti-DC-SIGN/CD209 murine monoclonal antibodies
Anti-DC-SIGN/CD209 murine monoclonal antibodies DC-SIGN (DC Specific, ICAM-3 Grabbing, Nonintegrin) / CD209 and L-SIGN (liver/lymph node-specific ICAM-3-grabbing nonintegrin CD299/ DC-SIGNR (DC-SIGN-related
More information(A) RT-PCR for components of the Shh/Gli pathway in normal fetus cell (MRC-5) and a
Supplementary figure legends Supplementary Figure 1. Expression of Shh signaling components in a panel of gastric cancer. (A) RT-PCR for components of the Shh/Gli pathway in normal fetus cell (MRC-5) and
More informationPrinciples of Adaptive Immunity
Principles of Adaptive Immunity Chapter 3 Parham Hans de Haard 17 th of May 2010 Agenda Recognition molecules of adaptive immune system Features adaptive immune system Immunoglobulins and T-cell receptors
More informationTITLE: Antibody - Pretargeted Cytokine Therapy of Cancer. CONTRACTING ORGANIZATION: Fox Chase Cancer Center Philadelphia, Pennsylvania 19111
k AD Award Number: DAMD17-99-1-9183 TITLE: Antibody - Pretargeted Cytokine Therapy of Cancer PRINCIPAL INVESTIGATOR: Louis Weiner, M.D. CONTRACTING ORGANIZATION: Fox Chase Cancer Center Philadelphia, Pennsylvania
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Nair S, Branagan AR, Liu J, Boddupalli CS, Mistry PK, Dhodapkar
More informationSUPPLEMENTARY INFORMATION
Supplementary Figures Supplementary Figure S1. Binding of full-length OGT and deletion mutants to PIP strips (Echelon Biosciences). Supplementary Figure S2. Binding of the OGT (919-1036) fragments with
More informationSupplementary Figure 1.
Supplementary Figure 1. Female Pro-ins2 -/- mice at 5-6 weeks of age were either inoculated i.p. with a single dose of CVB4 (1x10 5 PFU/mouse) or PBS and treated with αgalcer or control vehicle. On day
More informationProduct Datasheet. CD161/NK1.1 Antibody (PK136) NB Unit Size: 0.5 mg. Store at 4C. Do not freeze. Publications: 2
Product Datasheet CD161/NK1.1 Antibody (PK136) NB100-77528 Unit Size: 0.5 mg Store at 4C. Do not freeze. Publications: 2 Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
More informationFigure S1. Generation of inducible PTEN deficient mice and the BMMCs (A) B6.129 Pten loxp/loxp mice were mated with B6.
Figure S1. Generation of inducible PTEN deficient mice and the BMMCs (A) B6.129 Pten loxp/loxp mice were mated with B6.129-Gt(ROSA)26Sor tm1(cre/ert2)tyj /J mice. To induce deletion of the Pten locus,
More informationFigure S1. B % of Phosphorylation 32H. 32ss
Figure S1 8H 32ss 32H 32Hc % of Phosphorylation 3 32H 2 1 32ss 1 2 3 4 Extract (μg) C % of Phosphorylation 18 12 6-32H 32Hc 8H 32ss Dbait Figure S1. List of the Dbait molecules and activation of DN-PK
More informationFigure S1. PMVs from THP-1 cells expose phosphatidylserine and carry actin. A) Flow
SUPPLEMENTARY DATA Supplementary Figure Legends Figure S1. PMVs from THP-1 cells expose phosphatidylserine and carry actin. A) Flow cytometry analysis of PMVs labelled with annexin-v-pe (Guava technologies)
More informationSUPPLEMENTAL INFORMATION
SUPPLEMENTAL INFORMATION EXPERIMENTAL PROCEDURES Tryptic digestion protection experiments - PCSK9 with Ab-3D5 (1:1 molar ratio) in 50 mm Tris, ph 8.0, 150 mm NaCl was incubated overnight at 4 o C. The
More informationSupplementary Table 1. Characterization of HNSCC PDX models established at MSKCC
Supplementary Table 1. Characterization of HNSCC PDX models established at MSKCC Supplementary Table 2. Drug content and loading efficiency estimated with F-NMR and UV- Vis Supplementary Table 3. Complete
More informationBMDCs were generated in vitro from bone marrow cells cultured in 10 % RPMI supplemented
Supplemental Materials Figure S1. Cultured BMDCs express CD11c BMDCs were generated in vitro from bone marrow cells cultured in 10 % RPMI supplemented with 15 ng/ml GM-CSF. Media was changed and fresh
More informationChapter 11. B cell generation, Activation, and Differentiation. Pro-B cells. - B cells mature in the bone marrow.
Chapter B cell generation, Activation, and Differentiation - B cells mature in the bone marrow. - B cells proceed through a number of distinct maturational stages: ) Pro-B cell ) Pre-B cell ) Immature
More informationDual Targeting Nanoparticle Stimulates the Immune
Dual Targeting Nanoparticle Stimulates the Immune System to Inhibit Tumor Growth Alyssa K. Kosmides, John-William Sidhom, Andrew Fraser, Catherine A. Bessell, Jonathan P. Schneck * Supplemental Figure
More informationChapter 11. B cell generation, Activation, and Differentiation. Pro-B cells. - B cells mature in the bone marrow.
Chapter B cell generation, Activation, and Differentiation - B cells mature in the bone marrow. - B cells proceed through a number of distinct maturational stages: ) Pro-B cell ) Pre-B cell ) Immature
More informationSupplementary Figure 1: Co-localization of reconstituted L-PTC and dendritic cells
a CD11c Na + K + ATPase Na + K + ATPase CD11c x-y CD11c Na + K + ATPase Na + K + ATPase CD11c x-z c b x-y view BoNT NAPs CD11c BoNT CD11c NAPs BoNT NAPs CD11c 90 x-z view Apical Basolateral Supplementary
More informationSimultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity
Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity Filippa Fleetwood 1, Susanne Klint 2, Martin Hanze 1, Elin Gunneriusson
More informationSupplemental Material
Supplemental Material Supplementary Fig. 1. EETs stimulate primary tumor growth. a) Schematic presentation of genetic and pharmacological tools used to manipulate endogenous EET levels. b) Endothelial
More informationNature Immunology: doi: /ni Supplementary Figure 1. Gene expression profile of CD4 + T cells and CTL responses in Bcl6-deficient mice.
Supplementary Figure 1 Gene expression profile of CD4 + T cells and CTL responses in Bcl6-deficient mice. (a) Gene expression profile in the resting CD4 + T cells were analyzed by an Affymetrix microarray
More informationAcute lung injury in children : from viral infection and mechanical ventilation to inflammation and apoptosis Bern, R.A.
UvA-DARE (Digital Academic Repository) Acute lung injury in children : from viral infection and mechanical ventilation to inflammation and apoptosis Bern, R.A. Link to publication Citation for published
More informationSUPPLEMENTARY INFORMATION
Complete but curtailed T-cell response to very-low-affinity antigen Dietmar Zehn, Sarah Y. Lee & Michael J. Bevan Supp. Fig. 1: TCR chain usage among endogenous K b /Ova reactive T cells. C57BL/6 mice
More informationNKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies
NKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies Saul Kivimäe Senior Scientist, Research Biology Nektar Therapeutics NK Cell-Based Cancer Immunotherapy, September 26-27,
More informationNKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity
NKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity Peiwen Kuo Scientist, Research Biology Nektar Therapeutics August 31 st, 2018 Emerging
More informationNature Medicine: doi: /nm.4322
1 2 3 4 5 6 7 8 9 10 11 Supplementary Figure 1. Predicted RNA structure of 3 UTR and sequence alignment of deleted nucleotides. (a) Predicted RNA secondary structure of ZIKV 3 UTR. The stem-loop structure
More informationSupplementary Figure 1. Double-staining immunofluorescence analysis of invasive colon and breast cancers. Specimens from invasive ductal breast
Supplementary Figure 1. Double-staining immunofluorescence analysis of invasive colon and breast cancers. Specimens from invasive ductal breast carcinoma (a) and colon adenocarcinoma (b) were staining
More informationProduct Datasheet. HLA ABC Antibody (W6/32) NB Unit Size: 0.25 mg. Store at -20C. Avoid freeze-thaw cycles. Reviews: 1 Publications: 22
Product Datasheet HLA ABC Antibody (W6/32) NB100-64775 Unit Size: 0.25 mg Store at -20C. Avoid freeze-thaw cycles. Reviews: 1 Publications: 22 Protocols, Publications, Related Products, Reviews, Research
More informationNature Protocols: doi: /nprot Supplementary Figure 1
Supplementary Figure 1 Traditional electronic gating strategy for analysing cell death based on A5-FITC and 7-AAD. a, Flow cytometry analysis showing the traditional two-stage electronic gating strategy
More informationSUPPORTING INFORMATIONS
SUPPORTING INFORMATIONS Mice MT/ret RetCD3ε KO α-cd25 treated MT/ret Age 1 month 3 mnths 6 months 1 month 3 months 6 months 1 month 3 months 6 months 2/87 Survival 87/87 incidence of 17/87 1 ary tumor
More informationThe clathrin adaptor Numb regulates intestinal cholesterol. absorption through dynamic interaction with NPC1L1
The clathrin adaptor Numb regulates intestinal cholesterol absorption through dynamic interaction with NPC1L1 Pei-Shan Li 1, Zhen-Yan Fu 1,2, Ying-Yu Zhang 1, Jin-Hui Zhang 1, Chen-Qi Xu 1, Yi-Tong Ma
More informationSupplementary Information. Supplementary Figure 1
Supplementary Information Supplementary Figure 1 1 Supplementary Figure 1. Functional assay of the hcas9-2a-mcherry construct (a) Gene correction of a mutant EGFP reporter cell line mediated by hcas9 or
More informationSupplementary Figures
Supplementary Figures Supplementary Figure 1. NKT ligand-loaded tumour antigen-presenting B cell- and monocyte-based vaccine induces NKT, NK and CD8 T cell responses. (A) The cytokine profiles of liver
More informationIn situ drug-receptor binding kinetics in single cells: a quantitative label-free study of anti-tumor drug resistance
Supplementary Information for In situ drug-receptor binding kinetics in single cells: a quantitative label-free study of anti-tumor drug resistance Wei Wang 1, Linliang Yin 2,3, Laura Gonzalez-Malerva
More informationExcerpt from MACS&more Vol 17 1/2016. Kenji Miki¹, Koji Nagaoka¹, Hermann Bohnenkamp², Takayuki Yoshimoto³, Ryuji Maekawa¹*, and Takashi Kamigaki⁴
Excerpt from MCS&more Vol 17 1/2016 Dendritic cells pulsed with induce both OV-specific CD4 + and CD8 + T cells and cause antitumor effects in a mouse model of lymphoma Kenji Miki¹, Koji Nagaoka¹, Hermann
More informationSupplementary Figure 1 (previous page). EM analysis of full-length GCGR. (a) Exemplary tilt pair images of the GCGR mab23 complex acquired for Random
S1 Supplementary Figure 1 (previous page). EM analysis of full-length GCGR. (a) Exemplary tilt pair images of the GCGR mab23 complex acquired for Random Conical Tilt (RCT) reconstruction (left: -50,right:
More informationSupplementary Fig. 1: ATM is phosphorylated in HER2 breast cancer cell lines. (A) ATM is phosphorylated in SKBR3 cells depending on ATM and HER2
Supplementary Fig. 1: ATM is phosphorylated in HER2 breast cancer cell lines. (A) ATM is phosphorylated in SKBR3 cells depending on ATM and HER2 activity. Upper panel: Representative histograms for FACS
More informationSupplementary Figure 1. Deletion of Smad3 prevents B16F10 melanoma invasion and metastasis in a mouse s.c. tumor model.
A B16F1 s.c. Lung LN Distant lymph nodes Colon B B16F1 s.c. Supplementary Figure 1. Deletion of Smad3 prevents B16F1 melanoma invasion and metastasis in a mouse s.c. tumor model. Highly invasive growth
More informationSurface plasmon resonance (SPR) analysis
Surface plasmon resonance (SPR) analysis Soluble CD8αα and was manufactured as described previously. 1,2 The C12C heterodimeric TCR was produced using an engineered disulfide bridge between the constant
More informationSUPPLEMENTARY INFORMATION
DOI: 1.138/ncb3355 a S1A8 + cells/ total.1.8.6.4.2 b S1A8/?-Actin c % T-cell proliferation 3 25 2 15 1 5 T cells Supplementary Figure 1 Inter-tumoral heterogeneity of MDSC accumulation in mammary tumor
More informationERK1/2/MAPK pathway-dependent regulation of the telomeric factor TRF2
ERK1/2/MAPK pathway-dependent regulation of the telomeric factor TRF2 SUPPLEMENTARY FIGURES AND TABLE Supplementary Figure S1: Conservation of the D domain throughout evolution. Alignment of TRF2 sequences
More informationAlphaScreen : A Straightforward and Powerful Alternative to ELISA. Martina Bielefeld-Sévigny Ph.D., R&D Director
AlphaScreen : A Straightforward and Powerful Alternative to ELISA Martina Bielefeld-Sévigny Ph.D., R&D Director Overview AlphaScreen - an alternative to ELISA Why an alternative to ELISA? Assay principle
More information(a) Significant biological processes (upper panel) and disease biomarkers (lower panel)
Supplementary Figure 1. Functional enrichment analyses of secretomic proteins. (a) Significant biological processes (upper panel) and disease biomarkers (lower panel) 2 involved by hrab37-mediated secretory
More informationMHC class I MHC class II Structure of MHC antigens:
MHC class I MHC class II Structure of MHC antigens: MHC class I antigens consist of a transmembrane heavy chain (α chain) that is non-covalently associated with β2- microglobulin. Membrane proximal domain
More informationTITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer
AD Award Number: W8-XWH-5-- TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer PRINCIPAL INVESTIGATOR: Mathias Oelke, Ph.D. CONTRACTING ORGANIZATION: Johns Hopkins
More informationIgG3 regulates tissue-like memory B cells in HIV-infected individuals
SUPPLEMENTARY INFORMATION Articles https://doi.org/10.1038/s41590-018-0180-5 In the format provided by the authors and unedited. IgG3 regulates tissue-like memory B cells in HIV-infected individuals Lela
More informationSupplemental Information
Supplemental Information Tobacco-specific Carcinogen Induces DNA Methyltransferases 1 Accumulation through AKT/GSK3β/βTrCP/hnRNP-U in Mice and Lung Cancer patients Ruo-Kai Lin, 1 Yi-Shuan Hsieh, 2 Pinpin
More informationFluorescence Microscopy
Fluorescence Microscopy Imaging Organelles Mitochondria Lysosomes Nuclei Endoplasmic Reticulum Plasma Membrane F-Actin AAT Bioquest Introduction: Organelle-Selective Stains Organelles are tiny, specialized
More informationSupplementary Information
Supplementary Information Supplementary Figure 1. CD4 + T cell activation and lack of apoptosis after crosslinking with anti-cd3 + anti-cd28 + anti-cd160. (a) Flow cytometry of anti-cd160 (5D.10A11) binding
More informationMHC Tetramers and Monomers for Immuno-Oncology and Autoimmunity Drug Discovery
MHC Tetramers and Monomers for Immuno-Oncology and Autoimmunity Drug Discovery Your Partner in Drug Discovery and Research MHC Tetramer Background T-Cell Receptors recognize and bind to complexes composed
More informationSUPPLEMENTARY INFORMATION
doi:1.138/nature1554 a TNF-α + in CD4 + cells [%] 1 GF SPF 6 b IL-1 + in CD4 + cells [%] 5 4 3 2 1 Supplementary Figure 1. Effect of microbiota on cytokine profiles of T cells in GALT. Frequencies of TNF-α
More informationSupporting Information
Supporting Information lpek et al. 1.173/pnas.1121217 SI Materials and Methods Mice. cell knockout, inos / (Taconic arms), Rag1 /, INγR /, and IL-12p4 / mice (The Jackson Laboratory) were maintained and/or
More informationRecombinant Integrins
Recombinant Integrins Ligand INTEGRIN α subunit S S β subunit Recombinant Integrins Integrins are heterodimeric integral membrane proteins that play key roles in regulating cell-cell and cell-extracellular
More informationSupplementary Materials for
www.sciencetranslationalmedicine.org/cgi/content/full/8/352/352ra110/dc1 Supplementary Materials for Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy
More informationTargeting Oncogenic Drivers
Targeting Oncogenic Drivers Yujie Zhao Alex A. Adjei Department of Medicine, Roswell Park Cancer Institute, Buffalo, N.Y., USA Abstract Cancer is a genetic disease caused by a series of somatic and/or
More informationSupplementary Information. A vital role for IL-2 trans-presentation in DC-mediated T cell activation in humans as revealed by daclizumab therapy
Supplementary Information A vital role for IL-2 trans-presentation in DC-mediated T cell activation in humans as revealed by daclizumab therapy Simone C. Wuest 1, Jehad Edwan 1, Jayne F. Martin 1, Sungpil
More informationProduct Datasheet. EMMPRIN/CD147 Antibody (MEM-M6/1) NB Unit Size: 0.1 mg. Store at 4C. Do not freeze. Publications: 2
Product Datasheet EMMPRIN/CD147 Antibody (MEM-M6/1) NB500-430 Unit Size: 0.1 mg Store at 4C. Do not freeze. Publications: 2 Protocols, Publications, Related Products, Reviews, Research Tools and Images
More informationSupplementary Figures
Supplementary Figures Supplementary Figure 1 Characterization of stable expression of GlucB and sshbira in the CT26 cell line (a) Live cell imaging of stable CT26 cells expressing green fluorescent protein
More informationand follicular helper T cells is Egr2-dependent. (a) Diagrammatic representation of the
Supplementary Figure 1. LAG3 + Treg-mediated regulation of germinal center B cells and follicular helper T cells is Egr2-dependent. (a) Diagrammatic representation of the experimental protocol for the
More informationHow T cells recognize antigen: The T Cell Receptor (TCR) Identifying the TCR: Why was it so hard to do? Monoclonal antibody approach
How T cells recognize antigen: The T Cell Receptor (TCR) Identifying the TCR: Why was it so hard to do By the early 1980s, much about T cell function was known, but the receptor genes had not been identified
More informationA second type of TCR TCR: An αβ heterodimer
How s recognize antigen: The T Cell Receptor (TCR) Identifying the TCR: Why was it so hard to do By the early 1980s, much about function was known, but the receptor genes had not been identified Recall
More informationSupplementary Fig. 1 p38 MAPK negatively regulates DC differentiation. (a) Western blot analysis of p38 isoform expression in BM cells, immature DCs
Supplementary Fig. 1 p38 MAPK negatively regulates DC differentiation. (a) Western blot analysis of p38 isoform expression in BM cells, immature DCs (idcs) and mature DCs (mdcs). A myeloma cell line expressing
More informationPBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human
Anti-CD19-CAR transduced T-cell preparation PBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human AB serum (Gemini) and 300 international units/ml IL-2 (Novartis). T cell proliferation
More informationactivation with anti-cd3/cd28 beads and 3d following transduction. Supplemental Figure 2 shows
Supplemental Data Supplemental Figure 1 compares CXCR4 expression in untreated CD8 + T cells, following activation with anti-cd3/cd28 beads and 3d following transduction. Supplemental Figure 2 shows the
More informationSupporting Information
Supporting Information Pang et al. 10.1073/pnas.1322009111 SI Materials and Methods ELISAs. These assays were performed as previously described (1). ELISA plates (MaxiSorp Nunc; Thermo Fisher Scientific)
More informationIntroduction: 年 Fas signal-mediated apoptosis. PI3K/Akt
Fas-ligand (CD95-L; Fas-L) Fas (CD95) Fas (apoptosis) 年 了 不 度 Fas Fas-L 力 不 Fas/Fas-L T IL-10Fas/Fas-L 不 年 Fas signal-mediated apoptosis 度降 不 不 力 U-118, HeLa, A549, Huh-7 MCF-7, HepG2. PI3K/Akt FasPI3K/Akt
More informationFigure S1 Time-dependent down-modulation of HER3 by EZN No Treatment. EZN-3920, 2 μm. Time, h
Figure S1 Time-dependent down-modulation of HER3 by EZN-392 HE ER3 mrna A, %Contr rol 12 No Treatment EZN-392, 2 μm 1 8 6 4 2 2 8 24 Time, h Figure S2. Specific target down-modulation by HER3 (EZN-392)
More informationSupplementary Figures
Supplementary Figures Supplementary Fig. 1. Surface thiol groups and reduction of activated T cells. (a) Activated CD8 + T-cells have high expression levels of free thiol groups on cell surface proteins.
More informationHIV Immunopathogenesis. Modeling the Immune System May 2, 2007
HIV Immunopathogenesis Modeling the Immune System May 2, 2007 Question 1 : Explain how HIV infects the host Zafer Iscan Yuanjian Wang Zufferey Abhishek Garg How does HIV infect the host? HIV infection
More informationHidenobu Kanda, Rebecca Newton, Russell Klein, Yuka Morita, Michael D. Gunn & Steven D. Rosen
Autotaxin, a lysophosphatidic acid-producing ectoenzyme, promotes lymphocyte entry into secondary lymphoid organs Hidenou Kanda, Reecca Newton, Russell Klein, Yuka Morita, Michael D. Gunn & Steven D. Rosen
More informationEndogenous TNFα orchestrates the trafficking of neutrophils into and within lymphatic vessels during acute inflammation
SUPPLEMENTARY INFORMATION Endogenous TNFα orchestrates the trafficking of neutrophils into and within lymphatic vessels during acute inflammation Samantha Arokiasamy 1,2, Christian Zakian 1, Jessica Dilliway
More informationSupplementary Figures
Supplementary Figures Supplementary Figure 1. Confirmation of Dnmt1 conditional knockout out mice. a, Representative images of sorted stem (Lin - CD49f high CD24 + ), luminal (Lin - CD49f low CD24 + )
More informationHuman Immunodeficiency Virus Type-1 Myeloid Derived Suppressor Cells Inhibit Cytomegalovirus Inflammation through Interleukin-27 and B7-H4
Human Immunodeficiency Virus Type-1 Myeloid Derived Suppressor Cells Inhibit Cytomegalovirus Inflammation through Interleukin-27 and B7-H4 Ankita Garg, Rodney Trout and Stephen A. Spector,,* Department
More informationSupplementary Materials and Methods
Supplementary Materials and Methods Hepatocyte toxicity assay. Freshly isolated hepatocytes were incubated for overnight with varying concentrations (-25 µm) of sodium glycochenodeoxycholate (GCDC) or
More informationStructure and Function of Antigen Recognition Molecules
MICR2209 Structure and Function of Antigen Recognition Molecules Dr Allison Imrie allison.imrie@uwa.edu.au 1 Synopsis: In this lecture we will examine the major receptors used by cells of the innate and
More informationCell isolation. Spleen and lymph nodes (axillary, inguinal) were removed from mice
Supplementary Methods: Cell isolation. Spleen and lymph nodes (axillary, inguinal) were removed from mice and gently meshed in DMEM containing 10% FBS to prepare for single cell suspensions. CD4 + CD25
More informationIMMUNE CELL SURFACE RECEPTORS AND THEIR FUNCTIONS
LECTURE: 07 Title: IMMUNE CELL SURFACE RECEPTORS AND THEIR FUNCTIONS LEARNING OBJECTIVES: The student should be able to: The chemical nature of the cellular surface receptors. Define the location of the
More informationSupplementary Information Supplementary Fig. 1. Elevated Usp9x in melanoma and NRAS mutant melanoma cells are dependent on NRAS for 3D growth.
Supplementary Information Supplementary Fig. 1. Elevated Usp9x in melanoma and NRAS mutant melanoma cells are dependent on NRAS for 3D growth. a. Immunoblot for Usp9x protein in NRAS mutant melanoma cells
More information